In part one, Alan Wein is joined by Melissa Kaufman, who chaired the AUA Guideline Committee on Genitourinary Syndrome of Menopause (GSM), to discuss these guidelines. Dr. Kaufman emphasizes the ...

Women who complain of bladder pain and urinary urgency and frequency wait years to receive the label of interstitial cystitis (IC), an "orphan disease" which has no known cause or cure. The current ...

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...

Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Alan Bryce interviews Tanya Dorff about recommendations from the 2024 US Prostate Cancer Consensus Conference addressing clinical gray areas in prostate cancer management.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

EVOLUTION study, lutetium PSMA-617, prostate cancer immunotherapy, checkpoint inhibitors, metastatic castration-resistant prostate cancer, EVOLUTION Trial: Ipilimumab/Nivolumab Plus Lutetium-PSMA ...

Developing effective strategies to prevent biofilm formation on urinary catheter surfaces is critical for reducing catheter-associated urinary tract infections (CAUTIs) in clinical settings. In this ...

(UroToday.com) Dr. Banna Hussain presented important new data from the Michigan Urological Surgery Improvement Collaborative (MUSIC), shedding light on the real-world implementation and outcomes of ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

HIF-2 inhibitor kidney cancer, Casdatifan cabozantinib combination, refractory renal cell carcinoma treatment, AB-521 clinical trial, clear cell RCC therapy, Combination HIF-2α/VEGF Dual Inhibition in ...